MA53667A - Polythérapie associant un composé d'acylthiourée et de l'abiratérone - Google Patents

Polythérapie associant un composé d'acylthiourée et de l'abiratérone

Info

Publication number
MA53667A
MA53667A MA053667A MA53667A MA53667A MA 53667 A MA53667 A MA 53667A MA 053667 A MA053667 A MA 053667A MA 53667 A MA53667 A MA 53667A MA 53667 A MA53667 A MA 53667A
Authority
MA
Morocco
Prior art keywords
polytherapy
abiraterone
combining
acylthiourea compound
acylthiourea
Prior art date
Application number
MA053667A
Other languages
English (en)
Inventor
Yuko Ishibashi
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA53667A publication Critical patent/MA53667A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA053667A 2018-09-18 2019-09-18 Polythérapie associant un composé d'acylthiourée et de l'abiratérone MA53667A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018174221 2018-09-18

Publications (1)

Publication Number Publication Date
MA53667A true MA53667A (fr) 2021-07-28

Family

ID=69887227

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053667A MA53667A (fr) 2018-09-18 2019-09-18 Polythérapie associant un composé d'acylthiourée et de l'abiratérone

Country Status (7)

Country Link
US (1) US20210369739A1 (fr)
EP (1) EP3854395A4 (fr)
JP (1) JP7540946B2 (fr)
KR (1) KR20210060465A (fr)
AU (1) AU2019342447B2 (fr)
MA (1) MA53667A (fr)
WO (1) WO2020059744A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011097A (es) 2008-04-10 2010-11-01 Taiho Pharmaceutical Co Ltd Compuesto de aciltiourea o sal del mismo, y uso del mismo.
TWI594986B (zh) 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
US20140011992A1 (en) * 2012-12-20 2014-01-09 Crystal Pharma, S.A.U. Synthesis of abiraterone and related compounds
HK1221424A1 (zh) 2013-04-04 2017-06-02 Exelixis, Inc. 治疗癌症的药物组合
US9149471B2 (en) 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
WO2016175305A1 (fr) 2015-04-30 2016-11-03 大鵬薬品工業株式会社 Sel d'acide mésylique de composé d'acylthiourée, cristaux de lui-ci, et procédés pour le produire
US10449189B2 (en) 2015-06-25 2019-10-22 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fibrosis
DK3583943T3 (da) 2017-02-15 2024-10-14 Taiho Pharmaceutical Co Ltd Farmaceutisk sammensætning

Also Published As

Publication number Publication date
JP7540946B2 (ja) 2024-08-27
US20210369739A1 (en) 2021-12-02
EP3854395A1 (fr) 2021-07-28
JPWO2020059744A1 (ja) 2021-08-30
WO2020059744A1 (fr) 2020-03-26
AU2019342447A1 (en) 2021-04-08
AU2019342447B2 (en) 2025-05-29
EP3854395A4 (fr) 2022-06-15
KR20210060465A (ko) 2021-05-26

Similar Documents

Publication Publication Date Title
IL283692A (en) Novel composition
DK4151637T3 (da) Gadolinium-indeholdende pcta-baserede kontrastmidler
EP3735685C0 (fr) Panneau d'affichage
EP3816154A4 (fr) Composé hétérocyclique et son application
IL282998A (en) Pyridazinone compounds and uses thereof
EP3802254A4 (fr) Planification de trajectoire
IL278122B1 (en) Pteridinone compounds and uses thereof
MA52090A (fr) Polythérapie
EP3960255A4 (fr) Équipement d'exercice
EP3808747A4 (fr) Composé d'imidazopyridinone
EP3978468A4 (fr) Composé et composition
EP3767786A4 (fr) Équipement de construction
DK3794619T3 (da) Fotovoltaisk indretning
EP3904481A4 (fr) Composé de silane et composition associée
EP3932909A4 (fr) Composé de benzoindazolone et intermédiaire de celui-ci
EP3868235A4 (fr) Gant
EP3984534A4 (fr) Composé de diarylamide et son application
MA54243A (fr) Composé de 1,3,4-oxadiazolone et médicament
DK3556683T3 (da) Fastgørelsesbånd
EP3792257A4 (fr) Composé de défactinib deutéré et son utilisation
EP3778119A4 (fr) Dresseur
EP3892144A4 (fr) Gant
EP3901146A4 (fr) Composé phénylpyrrolidine et son utilisation
EP3883416C0 (fr) Gant
EP3794944A4 (fr) Agent de réduction de phytotoxicité